Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Endonovo Therapeutics (ENDV) Net Income towards Common Stockholders (2016 - 2023)

Endonovo Therapeutics has reported Net Income towards Common Stockholders over the past 12 years, most recently at -$480278.0 for Q3 2023.

  • Quarterly results put Net Income towards Common Stockholders at -$480278.0 for Q3 2023, up 20.4% from a year ago — trailing twelve months through Sep 2023 was -$11.8 million (down 7.91% YoY), and the annual figure for FY2022 was -$18.5 million, down 495.02%.
  • Net Income towards Common Stockholders for Q3 2023 was -$480278.0 at Endonovo Therapeutics, down from $2.1 million in the prior quarter.
  • Over the last five years, Net Income towards Common Stockholders for ENDV hit a ceiling of $4.3 million in Q1 2020 and a floor of -$12.9 million in Q4 2022.
  • Median Net Income towards Common Stockholders over the past 5 years was -$1.5 million (2021), compared with a mean of -$2.4 million.
  • Biggest five-year swings in Net Income towards Common Stockholders: soared 280.3% in 2020 and later tumbled 639.66% in 2022.
  • Endonovo Therapeutics' Net Income towards Common Stockholders stood at -$5.7 million in 2019, then surged by 64.16% to -$2.0 million in 2020, then surged by 218.03% to $2.4 million in 2021, then tumbled by 639.66% to -$12.9 million in 2022, then soared by 96.29% to -$480278.0 in 2023.
  • The last three reported values for Net Income towards Common Stockholders were -$480278.0 (Q3 2023), $2.1 million (Q2 2023), and -$496759.0 (Q1 2023) per Business Quant data.